argenx SE (ARGX.BR)
ARGX.BR on Brussels Stock Exchange
109.80EUR
10:49am GMT
109.80EUR
10:49am GMT
Change (% chg)
€3.20 (+3.00%)
€3.20 (+3.00%)
Prev Close
€106.60
€106.60
Open
€109.80
€109.80
Day's High
€113.80
€113.80
Day's Low
€109.40
€109.40
Volume
59,399
59,399
Avg. Vol
123,236
123,236
52-wk High
€113.80
€113.80
52-wk Low
€54.30
€54.30
About
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)
Overall
| Beta: | 0.58 |
| Market Cap(Mil.): | €4,018.02 |
| Shares Outstanding(Mil.): | 37.69 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARGX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 88.11 | 35.99 |
| EPS (TTM): | -1.63 | -- | -- |
| ROI: | -- | 10.12 | 12.72 |
| ROE: | -- | 10.40 | 13.73 |
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.
Estimates